PHILIP RICH: Open Payments
NPI 1235108804 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,031 in 68 payments from 10 companies in 2025. Trend: 2023 $477 · 2024 $1,185 · 2025 $1,031
Food & beverage: $1,031
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $261 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $211 |
| Vanda Pharmaceuticals Inc. | 15 | $174 |
| Alkermes, Inc. | 3 | $84 |
| Supernus Pharmaceuticals, Inc. | 4 | $77 |
| Otsuka America Pharmaceutical, Inc. | 5 | $76 |
| Almatica Pharma LLC | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| E.R. Squibb & Sons, L.L.C. | 2 | $35 |
| Lundbeck LLC | 1 | $16 |
Products named: VRAYLAR, CAPLYTA, FANAPT, REXULTI, ARISTADA, Qelbree, LOREEV XR, TRINTELLIX.
Industry payments across NV — which companies pay providers there.
